$VNOV

VitaNova Life Sciences Corp

CIK:0001699709|SEC Filings

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Jul. 31, 2026	Jul. 31, 2025
Income Statement [Abstract]
Revenue, net	$ 321,576	$ 103,899
Cost of revenue	(291,055)	(35,118)
Gross profit	30,521	68,781
Operating expenses
Personnel and benefit costs	(37,852)	(34,928)
General and administrative expenses	(114,831)	(66,293)
Total operating expenses	(152,683)	(101,221)
Income from operations	(122,162)	(32,440)
Income tax expense	(939)	(13,861)
Net income (loss)	$ (123,101)	$ (46,301)
Net income (loss) per share - basic	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding - basic	8,337,454	8,337,454

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Jul. 31, 2026	Jul. 31, 2025
Cash flows from operating activities:
Net loss	$ (123,101)	$ (46,301)
Changes in operating assets and liabilities:
Accounts receivable	409,872	252,669
Prepayment	0	(10,083)
Inventories	(195,681)	35,118
Accounts payable	(86,008)	7,366
Accrued expenses and other current liabilities	944	406
Deferred revenue	0	10,775
Income tax payable	939	13,861
Net cash provided by operating activities	6,965	263,811
Net change in cash	6,965	263,811
Cash, beginning of period	1,597,217	782,810
Cash, end of period	1,604,182	1,046,621
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid	0	0
Income taxes paid	$ 0	$ 0

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jul. 31, 2026	Apr. 30, 2026
Current assets:
Cash	$ 1,604,182	$ 1,597,217
Accounts receivable, net	316,871	726,743
Inventories	301,294	105,613
Other current assets	950	950
Total current assets	2,223,297	2,430,523
Noncurrent assets:
Deferred tax assets	16,038	16,038
Total noncurrent assets	16,038	16,038
TOTAL ASSETS	2,239,335	2,446,561
Current liabilities:
Accounts payable	122,805	208,813
Accrued expenses and other current liabilities	79,903	78,959
Income tax payable	108,948	108,009
Total current liabilities	311,656	395,781
TOTAL LIABILITIES	311,656	395,781
Commitments and Contingencies
Shareholders’ equity
Preferred Stock, $0.001 par value; 10,000,000 shares authorized, including 3,000,000 shares of Series A Preferred Stock designated; nil shares issued and outstanding	0	0
Common Stock, $0.001 par value; 200,000,000 shares authorized; 8,337,454 shares issued and outstanding	8,337	8,337
Additional paid-in capital	1,029,646	1,029,646
Shares to be issued	182,400	182,400
Retained earnings	707,296	830,397
Total Shareholders’ Equity	1,927,679	2,050,780
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,239,335	$ 2,446,561